Your browser is no longer supported. Please, upgrade your browser.
ACRS Aclaris Therapeutics, Inc. weekly Stock Chart
ACRS [NASD]
Aclaris Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.16 Insider Own5.00% Shs Outstand29.46M Perf Week-4.35%
Market Cap718.82M Forward P/E- EPS next Y-4.22 Insider Trans7.96% Shs Float26.91M Perf Month1.16%
Income-57.10M PEG- EPS next Q-0.91 Inst Own92.00% Short Float10.60% Perf Quarter-9.73%
Sales0.70M P/S1026.89 EPS this Y-95.70% Inst Trans-4.24% Short Ratio8.05 Perf Half Y-16.35%
Book/sh8.47 P/B2.88 EPS next Y-62.90% ROA-29.20% Target Price44.40 Perf Year-12.07%
Cash/sh7.74 P/C3.15 EPS next 5Y66.00% ROE-30.80% 52W Range21.32 - 33.25 Perf YTD-1.05%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-26.62% Beta-
Dividend %- Quick Ratio23.40 Sales past 5Y- Gross Margin33.80% 52W Low14.45% ATR1.09
Employees31 Current Ratio23.40 Sales Q/Q- Oper. Margin- RSI (14)50.71 Volatility5.97% 4.14%
OptionableYes Debt/Eq0.00 EPS Q/Q-26.30% Profit Margin- Rel Volume0.90 Prev Close24.26
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 BMO Payout- Avg Volume354.12K Price24.40
Recom1.30 SMA200.12% SMA503.35% SMA200-6.20% Volume319,680 Change0.58%
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
Jan-08-18 11:40AM  Malvern firm's common warts treatment show promise in mid-stage testing American City Business Journals
07:00AM  Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts GlobeNewswire
Jan-04-18 04:01PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Dec-19-17 07:00AM  Aclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with Vitiligo GlobeNewswire
Dec-18-17 07:20AM  Blog Exposure - FDA Approves Aclaris Therapeutics' ESKATA Topical Solution for Treatment of Common Skin Growths ACCESSWIRE
Dec-15-17 09:21AM  Stocks to Watch: CSX, Hess, Adobe, Costco, Aclaris Therapeutics The Wall Street Journal
08:19AM  Aclaris's drug to treat common skin growth gets FDA nod Reuters
07:00AM  Aclaris Therapeutics Receives FDA Approval for ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs) GlobeNewswire
Dec-13-17 02:21PM  Aclaris Therapeutics, Inc. Value Analysis (NASDAQ:ACRS) : December 13, 2017 Capital Cube
Dec-12-17 07:22AM  Aclaris Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACRS-US : December 12, 2017 Capital Cube
Dec-07-17 06:00AM  Epidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards Lifesciences PR Newswire
Nov-30-17 08:18AM  5 Biotech and Pharma Stocks with FDA Catalysts this December Zacks
Nov-21-17 08:00AM  Aclaris Therapeutics Presents New Data at American College of Rheumatology Annual Meeting For ATI-450, a MK2 pathway Inhibitor GlobeNewswire
Nov-09-17 04:05PM  Aclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly GlobeNewswire
04:34AM  Edited Transcript of ACRS earnings conference call or presentation 7-Nov-17 1:00pm GMT Thomson Reuters StreetEvents
Nov-07-17 07:25AM  Aclaris reports 3Q loss Associated Press -8.45%
07:00AM  Aclaris Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-03-17 08:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
Nov-02-17 08:00AM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Oct-31-17 08:00AM  Aclaris Therapeutics to Announce Third Quarter 2017 Financial Results on November 7, 2017 GlobeNewswire
Oct-24-17 08:00AM  Aclaris Therapeutics Announces the Allowance of a U.S. Patent Application and Issuance of a Japanese Patent Covering Tofacitinib for Treating Hair Loss Disorders GlobeNewswire
Oct-06-17 07:46PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-20-17 08:00AM  Aclaris Therapeutics to Host R&D and Investor Event on October 4, 2017 in New York GlobeNewswire
Sep-19-17 08:00AM  Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis GlobeNewswire
Sep-07-17 04:01PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-05-17 08:00AM  Aclaris Therapeutics Announces Issuance of Two U.S. Patents Covering JAK Inhibitors for Treating Hair Loss Disorders GlobeNewswire
Aug-17-17 08:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire -5.00%
Aug-12-17 08:16AM  Edited Transcript of ACRS earnings conference call or presentation 8-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 07:40PM  Aclaris Announces Pricing of Public Offering of Common Stock GlobeNewswire -14.65%
Aug-09-17 04:01PM  Aclaris Announces Proposed Public Offering of Common Stock GlobeNewswire
08:00AM  Aclaris Announces Appointment of Andrew Schiff to Board of Directors GlobeNewswire
Aug-08-17 11:54PM  Aclaris reports 2Q loss Associated Press
06:06PM  [$$] Aclaris Therapeutics Buys Confluence Life Sciences in $100 Million Deal The Wall Street Journal
07:01AM  Aclaris Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
07:00AM  Aclaris Therapeutics Acquires Confluence Life Sciences, Inc. GlobeNewswire
05:50AM  Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 08:00AM  Aclaris Therapeutics Submits Marketing Authorization Application in Europe for A-101 40% Topical Solution as a Novel Treatment for Seborrheic Keratosis GlobeNewswire
Aug-02-17 08:00AM  Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata GlobeNewswire
Aug-01-17 08:56AM  UPDATE - Aclaris Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017 GlobeNewswire
08:00AM  Aclaris Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017 GlobeNewswire
Jun-29-17 08:00AM  Aclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts GlobeNewswire
Jun-13-17 08:00AM  Aclaris Therapeutics Announces Issuance of New U.S. Patent For A-101 Topical Solutions GlobeNewswire
May-09-17 06:08PM  Aclaris reports 1Q loss Associated Press
05:48PM  Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 GlobeNewswire
04:05PM  FDA Accepts Aclaris Therapeutics New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition GlobeNewswire
04:01PM  Aclaris Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
01:15PM  Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call Accesswire
May-05-17 08:00AM  Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis GlobeNewswire
May-01-17 04:08PM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
04:08PM  Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 GlobeNewswire
Apr-26-17 07:00AM  Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution GlobeNewswire
Apr-24-17 08:00AM  Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Dermatology Meeting GlobeNewswire
Apr-04-17 08:00AM  Aclaris Therapeutics Announces Notice of Allowance for Two U.S. Patent Applications Covering Baricitnib and Decernotinib, Respectively, for Hair Loss Disorders GlobeNewswire
08:00AM  Aclaris Therapeutics Announces Notice of Allowance for Two U.S. Patent Applications Covering Baricitnib and Decernotinib, Respectively, for Hair Loss Disorders
Mar-18-17 01:04PM  ACLARIS THERAPEUTICS, INC. Financials
Mar-15-17 07:25PM  Edited Transcript of ACRS earnings conference call or presentation 15-Mar-17 12:00pm GMT Thomson Reuters StreetEvents
07:25PM  Edited Transcript of ACRS earnings conference call or presentation 15-Mar-17 12:00pm GMT
08:00AM  Aclaris Therapeutics Inc Earnings Call scheduled for 8:00 am ET today
07:23AM  Aclaris reports 4Q loss Associated Press
07:23AM  Aclaris reports 4Q loss
07:16AM  ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  Q4 2016 Aclaris Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update GlobeNewswire
Mar-01-17 09:22AM  Humana (HUM) Includes Methodist Healthcare in its Network
Feb-27-17 08:00AM  Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis a Common Skin Condition GlobeNewswire
Feb-24-17 08:45AM  Aclaris Therapeutics (ACRS) Worth a Look: Stock Rises 8.5% Zacks
08:45AM  Aclaris Therapeutics (ACRS) Worth a Look: Stock Rises 8.5%
Feb-23-17 08:00AM  Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017 GlobeNewswire +8.57%
Feb-06-17 04:08PM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
02:01PM  Skin Lesion Drug Only Scratches the Surface, Says Aclaris CEO TheStreet.com
02:01PM  Skin Lesion Drug Only Scratches the Surface, Says Aclaris CEO
Jan-26-17 08:31AM  ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
08:00AM  Aclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors GlobeNewswire
Jan-03-17 08:44AM  Why Aclaris Therapeutics (ACRS) Stock Might be a Great Pick
08:00AM  Aclaris to Present at 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-09-16 06:00AM  Aclaris Therapeutics Inc (ACRS) Hedge Funds Are Snapping Up at Insider Monkey
Dec-07-16 08:00AM  Aclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, for the Treatment of Alopecia Totalis and Alopecia Universalis GlobeNewswire
Dec-02-16 11:00AM  Why Aclaris (ACRS) Could Be Positioned for a Surge
Nov-30-16 08:45AM  Aclaris Therapeutics (ACRS) Worth Watching: Stock Up 7.5%
Nov-29-16 07:07AM  Coverage initiated on Aclaris Therapeutics by Leerink Partners +7.49%
Nov-28-16 03:29PM  Edited Transcript of ACRS earnings conference call or presentation 3-Nov-16 12:30pm GMT
02:18PM  Aclaris Therapeutics, Inc. :ACRS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
Nov-22-16 08:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
Nov-19-16 05:10PM  Aclaris Files for Secondary Offering
Nov-18-16 04:12PM  ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St +9.07%
12:50PM  Pharma company targeting skin disorders plans $91M stock sale at bizjournals.com
Nov-17-16 07:03PM  Aclaris Announces Pricing of Public Offering of Common Stock GlobeNewswire
11:00AM  Why Aclaris Therapeutics, Inc. Stock Is Down Today at Motley Fool
Nov-16-16 04:05PM  Aclaris Announces Proposed Public Offering of Common Stock GlobeNewswire
11:13AM  Aclaris Announces Phase 3 Results, Will Submit NDA In Q1 2017
Nov-15-16 05:00PM  Aclaris Therapeutics Inc Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis Call scheduled for 5:00 pm ET today
04:31PM  ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:09PM  Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition GlobeNewswire
04:08PM  Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition GlobeNewswire
Nov-03-16 09:45AM  Malvern pharma firm wants to begin human testing of hair loss disease treatment at bizjournals.com
09:26AM  Aclaris reports 3Q loss
08:30AM  Aclaris Therapeutics Inc Earnings Call scheduled for 8:30 am ET today
07:36AM  ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  Q3 2016 Aclaris Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Aclaris Therapeutics Reports Third Quarter 2016 Financial Results GlobeNewswire
Developing a proprietary hydrogen peroxide treatment for common skin lesions.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHIFF ANDREW NDirectorAug 16Buy23.02108,6012,499,995634,455Aug 16 04:45 PM
Molineaux Christopher P.DirectorMar 17Option Exercise0.517,6053,8727,605Mar 21 08:43 PM
VIVO VENTURES VII, LLC10% OwnerMar 02Sale31.20125,0003,900,00060,972Mar 02 08:44 PM
VIVO VENTURES VII, LLC10% OwnerMar 01Sale30.98100,0003,098,00063,638Mar 02 08:44 PM
VIVO VENTURES VII, LLC10% OwnerFeb 28Sale30.50200,0006,100,00065,771Mar 02 08:44 PM